Intracellular signaling pathways activated by both PDGF and basic fibroblast growth factor (bFGF) have been implicated in the migration of vascular smooth muscle cells (VSMC), a key step in the pathogenesis of many vascular diseases. We demonstrate here that, while bFGF is a weak chemoattractant for VSMCs, it is required for the PDGFdirected migration of VSMCs and the activation of calcium/ calmodulin-dependent protein kinase II (CamKinase H), an intracellular event that we have previously shown to be important in the regulation of VSMC migration. Neutralizing antibodies to bFGF caused a dramatic reduction in the size of the intracellular calcium transient normally seen after PDGF stimulation and inhibited both PDGF-directed VSMC migration and CamKinase II activation. Partially restoring the calcium transient with ionomycin restored migration and CamKinase H activation as did the forced expression of a mutant CamKinase H that had been "locked" in the active state by site-directed mutagenesis. These results suggest that bFGF links PDGF receptor stimulation to changes in intracellular calcium and CamKinase II activation, reinforcing the central role played by CamKinase II in regulating VSMC migration. (J.
Introduction
Many vascular diseases are characterized by the abnormal accumulation of vascular smooth muscle cells (VSMC)1 in the tunica intima of blood vessels, a process which is thought to occur in part as a result of the migration of these cells from the tunica media (1, 2) . A large number of cytokines, growth factors, and other bioregulatory molecules have been implicated in this phenomena. PDGF is one of the most potent chemoattractants for VSMCs (3) . Based on the facts that platelet depletion inhibits intimal thickening in balloon catheter-injured rat arteries without affecting medial VSMC replication (4) , that a PDGFneutralizing antibody causes a 40% reduction in neointimal formation in the same animal model (5) , and that marked intimal VSMC accumulation has been observed after exogenous administration of PDGF (6) , it is likely that PDGF plays an important role in vivo as a mediator of migration. We previously showed that the migration of VSMCs in vitro is dependent not only on the presence of a gradient of PDGF but also on the phenotypic state of the cells (7) . Recently, we demonstrated that the PDGFdirected migration of VSMCs requires activation of the intracellular signaling pathway leading to the activation of calcium/ calmodulin-dependent protein kinase II (CamKinase II) and that modulating the phenotype of VSMCs from the proliferating/synthetic state to one of growth arrest/differentiation inhibits the ability to activate this enzyme in response to PDGF. Activating CamKinase II in growth-arrested VSMCs, by either forced elevation of intracellular calcium or forced expression of a mutant CamKinase II that has been "locked" in the activated state by site-directed mutagenesis, restores the ability of these cells to migrate in response to PDGF (8) .
Basic fibroblast growth factor (bFGF), the prototypic member of a family of structurally related growth regulatory polypeptides, is a potent mitogen for a variety of cells (9) (10) (11) (12) and has been shown to be an important mediator of VSMC proliferation during the response to balloon-catheter injury in the rat. The administration of neutralizing antibodies to bFGF causes an 80% reduction in medial VSMC proliferation 2 d after injury to the carotid artery (13) , while the systemic infusion of recombinant bFGF in rats after balloon catheter denudation increases medial VSMC proliferation rate fivefold (14) . It has been proposed that bFGF also plays a critical role in the process of VSMC migration. Treatment of cultured bovine smooth muscle cells with a neutralizing antibody to bFGF reduces their PDGF-stimulated migration by > 50% after in vitro "wounding" of the culture (15) , indicating that the chemotactic effect of PDGF requires bFGF. PDGF was also reported to induce a significant increase in bFGF mRNA expression in these cells. In vivo studies ( 16) support a critical role for bFGF in VSMC migration. The migration of VSMCs from the media to the neointima is dependent on a gradient of PDGF released from platelets attached to the deendothelialized vessel. There is no significant movement of cells after gentle deendothelialization in which the underlying medial layer is not injured unless bFGF is administered immediately after the procedure. Like-wise, the increased migration of VSMCs that accompanies more traumatic injury to the vessel and involves mechanical disruption of the tunica media is prevented by intravenous injection of an antibody that blocks bFGF's biological actions ( 16) .
These observations prompted us to investigate the effects of bFGF on PDGF-induced migration and PDGF-stimulated activation of CamKinase II. We show here that bFGF plays a critical role in the PDGF-directed migration of VSMCs DMSO, aliquoted , and stored at -700C. Calmodulin (Upstate Biotechnology, Inc.) and autocamtide-2 (Peninsula Laboratories, Inc., Belmont, CA) were dissolved in water, aliquoted, and stored at -20'C. All reagents were used only once after thawing.
Cell culture. Medial VSMCs were obtained from the thoracic aortas of 3-mo-old Wistar rats using a modification (7) of the combined collagenase and elastase digestion method ( 17). The endothelia and adventitia were stripped from the vessel before digestion. Cells were maintained in DMEM/high glucose supplemented with 10% heat-inactivated FBS, 1 mM nonessential amino acids, 20 mM L-glutamine, 50 Ag/ml penicillin, 50 jig/ml streptomycin, and 10 Ag/ml neomycin (Gibco BRL) in a humidified 5% CO2 atmosphere at 37°C. Proliferating cells were used between the 7th and 14th passages and were harvested for migration assays or biochemical analyses between 50 and 80% confluence. Rat aortic medial VSMC lines containing stably integrated expression plasmids of full-length wild-type (WT) and activated (D3) cDNAs for the rat brain CamKinase II a-subunits have been previously described and characterized (8) .
RNA analysis. Total RNA was isolated from VSMC cultures by the guanidinium isothiocyanate procedure (18) . Northern blotting analyses were performed as previously described (7) using Church's buffer ( 19) as both prehybridization and hybridization solutions. The bFGF probe was a cDNA probe encompassing 395 bp of the rat bFGF translated region (20) an a gift of Dr. William L. Lowe (University of Iowa, Des Moines, IA). The rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe was a 330-bp cDNA probe obtained by PCR amplification of reverse-transcribed adult rat aorta mRNA using published nucleotide sequences (21) . The c-fos cDNA probe is also a PCRgenerated probe and has been described previously (22) . Both c-fos and GAPDH probes were completely sequenced by the dideoxy-mediated chain termination method (23) to verify complete matching with published DNA sequences. Northern blots were analyzed on a blot analyzer (Betascope 603; Betagen Corp., Waltham, MA) for quantitative analysis.
bFGF immunoassay. VSMCs were cultured in 35-mm culture dishes, treated with 10 ng/ml PDGF BB for the times indicated, and then harvested (24) by first rinsing the cultures in Dulbecco's PBS (D-PBS) and then overlaying them with 0.2 ml of D-PBS containing 2 mM EDTA, pH 8.0, 2 mM N-ethylmaleimide, and 1 mM PMSF. The plates were then subjected to four freeze/thaw cycles (liquid nitrogen, 10 min; 370C, 15 min). Extracts were collected into microcentrifuge tubes (1.5 ml) and clarified by centrifugation at 14,000 rpm for 15 min at 40C. Protein content of the extracts was assessed using the BCA protein assay reagent (Pierce Chemical Co., Rockford, IL). The cell lysates were stored at -80OC until bFGF quantification was performed using a commercially available solid phase ELISA (Quantikine FGF Basic Immunoassay Kit; R and D Systems).
VSMC migration assay. Migration assays were performed using a modified Boyden chamber as previously described (7, 25) . Polycarbonate filters (13-mm diameter, 8-pm pores, Nuclepore Corp., Pleasanton, CA) were first coated overnight with 100 gg/ml type I collagen (Upstate Biotechnology Inc.). Growth factors, chemoattractants, and other reagents were used at the concentrations indicated in the results and added when the cells were added to the upper chamber of the Boyden apparatus. To distinguish between chemotactic and chemokinetic effects, migration was compared under situations in which the chemoattractant was added only to the lower chamber of the Boyden chamber (chemotaxis) or to both upper and lower chambers (chemokinesis). The effects of the various cell treatments on cell attachment to the upper side of the filter were routinely monitored by counting cells on the filters after fixation and staining (7) . For (27) . CamKinase H activity in cellular extracts was measured using a synthetic peptide substrate (Autocamtide 2; Peninsula Laboratories [8] (28) . The ratio of these two channels was used to estimate intracellular calcium concentration ([Ca2+1i) (29) .
Confocal microscopy. VSMCs were cultured on glass coverslips and treated with 10 ng/ml PDGF BB for 8 h. The cells were then fixed overnight at 4°C in 3.7% formaldehyde in D-PBS. After washing with D-PBS containing 1% BSA (DPBS-BSA), the cells were exposed for 1 h to 10 ,g/ml of a mouse mAb to bFGF (05-118; Upstate Biotechnology, Inc.,). The coverslips were washed in DPBS-BSA for 30 To exclude any cross-reaction between the bFGF neutralizing antibodies and PDGF, we examined their effect on the ability of PDGF to induce c-fos mRNA. Fig. 3 preparations were preabsorbed with immobilized recombinant bFGF before their addition in the migration assay. The results of these experiments are shown in Fig. 4 , in which the ability of the various affinity-purified fractions are compared with unfractionated antibody. For both antibodies, affinity purification over a mixture of protein A and G (bars I and 5) did not significantly affect the ability of the antibodies to inhibit migration. Incubation of the antibodies with bFGF-charged heparinSepharose followed by protein A/G purification, however, substantially reduced the inhibitory effects of both antibodies (bars 2 and 6). As a control, both antibodies were also incubated with heparin-Sepharose incubated with BSA alone and then purified by protein A/G. These preparations were comparable in their ability to inhibit migration to that of untreated antibodies (bars 3 and 7), demonstrating that the effect of affinity purification is due primarily to absorption of antibodies reacting with bFGF and not with the heparin used to immobilize bFGF. Although the data shown in Fig. 4 (bars I and 5) exclude the possibility that VSMC chemoattractants present in the antibody preparations were short-circuiting the PDGF gradient, antibodies were added to both sides of the chamber in a series of experiments. The effect of adding antibody to both sides of the chamber was not significantly different from the inhibitory effect seen with antibody added only to the top chamber (bars 4 and 8).
When placed in the bottom chamber of the Boyden appara- tus, bFGF was a weak chemoattractant even over a broad range of concentrations (Fig. 5, closed squares) . While (8) . The effects of the neutralizing antibodies described above on cell migration led us to examine whether endogenous bFGF was involved in CamKinase II activation and/or activity. Activation of CamKinase II occurs as a result of autophosphorylation and was monitored by following the incorporation of radiolabeled phosphate into the enzyme. Cells were incubated with radiolabeled inorganic phosphate, treated with various growth factors and reagents, and a cellular extract was prepared. CamKinase II was immunoprecipitated from the extract and identified by autoradiography after separation of the immunoprecipitates by SDS-PAGE. The amount of radiolabeled phosphate in the CamKinase II band was then quantified. Fig. 6 A and B, shows representative autoradiographs of the cellular extracts after SDS-PAGE separation. As shown, the incorporation of radiolabeled phosphate into cellular CamKinase II dramatically increased with either a 1-min incubation with PDGF BB or a 2-min incubation with ionomycin. Incubation with bFGF alone, however, did not lead to labeling of CamKinase II. Preincubation of the cells with the neutralizing monoclonal bFGF antibody at a dose sufficient to block migration (5 jzg/ml) almost completely blocked CamKinase II phosphorylation in response to PDGF. A graphical representation of the results of this experiment and others is shown in Fig. 6 Similar results were obtained when CamKinase II enzyme activity, expressed as percent autonomous (i.e., calcium-independent) activity, was measured using a synthetic substrate (Fig. 6 C; filled bars) . Under unstimulated, basal conditions, 9.9±1.6% of total CamKinase II activity was found to be calcium independent. After the addition of PDGF or ionomycin, calcium-independent activity increased significantly (58.8±3.6% for PDGF and 44±2.5% for ionomycin the activity of the enzyme above basal levels (15.6±1.8%, P > 0.01 compared to control). The data in Fig. 6 C also show that bFGF on its own was not able to stimulate an increase in CamKinase II activity (12.8±2.2%; P > 0.01). Together, these results demonstrate that bFGF-neutralizing antibodies that block migration also block CamKinase II activation and activity in response to the chemoattractant, PDGF, an event previously shown to be essential for VSMC chemotaxis (8) .
VSMCs expressing constitutively activated CamKinase II are resistant to the effects of bFGF neutralization. If the neutralizing antibodies reduce PDGF-directed VSMC migration due to their ability to block the activation of CamKinase II, which normally occurs upon the addition of PDGF, then the migration of VSMCs overexpressing constitutively active (i.e., calcium/calmodulin-independent) CamKinase II cDNA should be unaffected by the antibodies. Fig. 7 shows the effect of bFGF neutralizing antibodies on the migration of VSMC cell lines containing stably integrated cDNAs for either WT or mutant (D3) CamKinase II a-subunits from rat brain. The mutation involved replacement of amino acids T286 and V287 with two aspartic acid (D) residues. T286 is the site of the autophosphorylation reaction involved in the activation of CamKinase II to its calcium/calmodulin-independent state and the amino acid substitutions described above introduce two constitutively negative charges into this region, mimicking the effect of autophosphorylation and producing a permanently activated CamKinase II molecule (8, 32) . The migration of these two stable cell lines toward PDGF was slightly greater than that of untransfected or vector alone-transfected cells ( Fig. 7 tion (64% inhibition; 43±4.4 cells/field, P <0.001) in these cells, while isotype-matched control Ig (for the mAb) had no effect on the migration of WT cells. As predicted, the monoclonal neutralizing antibody was completely ineffective in the mutant D3 cells overexpressing constitutively activated CamKinase II ( Fig. 7; 93.3±+0.7 cells/field; P > 0.2, NS from PDGFstimulated cells not treated with antibody).
Neutralizing antibodies against bFGF interfere with the intracellular calcium response to PDGF. PDGF BB causes a rapid and large increase in intracellular free calcium concentration ([Ca2+ ]i in proliferating VSMCs (8) . Both PDGF-directed VSMC migration and that endogenously produced bFGF is accessible to the neutralizing antibodies used in this study. While the data in Fig. 1 demonstrate that bFGF is produced by VSMCs, especially in response to PDGF, they do not indicate whether the growth factor is actually secreted by these cells, an important consideration given the fact that bFGF does not contain a secretory signal sequence (34) . Attempts to identify bFGF in the conditioned media of PDGF-treated VSMCs using an enzyme-linked immunoassay with a sensitivity greater than most bioassays (5 pg/ml ELISA vs 10-20 pg/ ml for NR6-3T3 proliferation assay [35] ) were all negative, suggesting that newly produced bFGF was either confined to the cells and/or secreted and bound to the extracellular matrix. To localize bFGF, confocal microscopic imaging of proliferating VSMCs with bFGF antibodies was performed (Fig. 10) .
Images of the cells were taken at the plane of the culture dish (level 0 tm) and at a level through the cell and its nucleus (level 2 tm) 8 h after treatment with PDGF BB. Fig. 10 , C and E shows staining at these levels with the bFGF antibody, while Fig. 10 the formation of the neointima after vascular injury has been reported, where it has been directly shown to be an important mediator of medial VSMC replication after vessel injury (13, 14) . In addition, bFGF induces angiogenesis (44) (45) (46) and stimulates the migration of endothelial cells (47) (48) (49) . Endogenous bFGF has also been shown to be an essential part of the mechanism by which thromboxane A2 stimulates hypertrophy of VSMCs (24) . Evidence that bFGF also affects the migration of VSMCs is supported by data in the literature. In vitro studies have shown that increased migration in response to PDGF occurs within 24 h of wounding a culture of VSMCs, is associated with an elevation in bFGF mRNA that peaks at -12 h, and is blocked by neutralizing antibodies to bFGF ( 15 ) . These studies, however, did not distinguish whether bFGF acted as a cofactor to facilitate migration toward PDGF or as a chemoattractant itself. Our studies indicate that bFGF is, at best, a weak chemoattractant for cultured rat VSMCs and that bFGF's role in PDGF-stimulated migration is to facilitate intracellular signaling required for migration.
Other studies indicate that bFGF may play an important role in the migration of VSMCs in vivo in response to vessel injury. In rat carotid arteries that have been deendothelialized with a balloon catheter, there is significantly more medial cell migration and neointima formation when traumatic injury to the underlying smooth muscle cell layers accompanies deendothelialization. Such injury is thought to facilitate migration by causing the release of bFGF from VSMCs when the integrity of their plasma membranes are compromised by the injury. Consistent with this interpretation is the observation that infusion of bFGFneutralization antibodies into such vessels blocks the increase in medial cell migration and neointima size (13) . In addition, the neointimal response to gentle deendothelialization can be increased by systemic injection of bFGF ( 16) . While these data cannot rule out the possibility that bFGF is acting as a VSMC chemoattractant on its own, it is clear that PDGF, which would be expected to be released from activated platelets that accumulate on the surface of the denuded vessel regardless of the extent of underlying medial cell injury, is not sufficient on its own to induce significant medial cell migration. Injury to the underlying media either releases a cofactor or enables cells to respond to a cofactor that is always present, thereby facilitating cell migration. The data we have presented here suggest that that factor may be bFGF. One test of this hypothesis will be to determine whether neutralizing PDGF antibodies block medial cell migration in gently deendothelialized vessels infused with bFGF.
The mechanism by which bFGF affects PDGF signal transduction and enables it to activate CamKinase II is not known. Both PDGF and bFGF interact with cell surface receptors that are ligand-activated tyrosine kinases (50, 51) . These kinases autophosphorylate the receptors, facilitating the docking and subsequent activation of a number of intracellular proteins that control different signaling transduction pathways (51 ) . Activation of phospholipase C-y (PLC-y) via its docking to the activated receptor would be the most direct pathway from receptor stimulation to CamKinase II activation. Activation of PLC-y leads to the the hydrolysis of phosphatidylinositol bisphosphate and the formation of diacylglycerol and inositoltriphosphate (UP3) (52) . IP3, through its ability to rapidly raise the intracellular calcium level through the release of calcium from intracellular stores (53) , then leads to activation of CamKinase 11 (54) . Our measurements of the changes in intracellular calcium levels in response to PDGF demonstrate that the early calcium release attributable to IP3 was dramatically truncated in bFGF antibody-treated cells (Fig. 8) . The addition of ionomycin, which causes a rapid increase in intracellular calcium similar to that seen in proliferating PDGF-stimulated cells (8) (Fig. 6 ). These results suggest that endogenous bFGF either affects the ability of PDGF to activate PLC-y, the ability of PLC-y to synthesize IP3, the content of calcium in intracellular stores, or the release of those stores by IP3.
Although the changes in intracellular calcium dynamics seen with antibody treatment currently provide a satisfactory explanation of the data, other possible mechanisms cannot be excluded. For example, bFGF can also activate protein kinase C (PKC) through PLCy-independent pathways (55, 56) . PKC, in turn, can potentiate the actions of CamKinase II by increasing the availability of cytosolic calmodulin (57, 58) . Antibodies that block bFGF could, therefore, interfere with CamKinase H activation by ultimately regulating calmodulin levels. Note, however, that downregulating PKC in proliferating VSMCs, thereby blocking the ability of either PDGF or bFGF to activate PKC, has been shown to have no effect on cell migration (8) . lonomycin's ability to restore migration in antibody treated cells, however, might be through an indirect effect on calmodulin levels and not solely through intracellular calcium content, although no such effects have been reported.
An additional complication to understanding the mechanism by which bFGF assists PDGF-directed migration in VSMCs is that bFGF does not contain a signal peptide sequence for secretion (34) . This fact and the observations that bFGF can be found in the nuclei of many different cells (59) has led to the suggestion that bFGF may not be required to exit the cell to initiate its effects (60) . Evidence for secretion by exocytosis that is independent of the endoplasmic reticulum-Golgi pathway, however, has been presented (61) and the micrographs in Fig. 10 E demonstrate that bFGF is present in the extracellular matrix surrounding VSMCs. Likewise, previous studies on VSMCs have clearly demonstrated the extracellular presence of VSMC-derived bFGF (49) . Exogenously applied bFGF can restore the ability of growth-arrested VSMCs to migrate toward PDGF. This restoration is associated with the ability of these cells to activate CamKinase II in response to PDGF (Bilato, C., R. Pauly, R. Monticone, and M. Crow, unpublished observations), a result consistent with the studies described here and an extracellular mode of bFGF action.
In summary, we have shown that bFGF, which is necessary for both in vivo and in vitro migration of VSMCs, is required for PDGF to complete the intracellular signaling needed for in vitro migration. While multiple intracellular signaling pathways are likely to be required for a complex cellular behavior such as migration, the data presented here reinforce the central role of CamKinase II activation in the regulation of that behavior in VSMCs. The results indicate that multiple growth factors/ cytokines may be needed to activate the program of cell migration in VSMCs. This requirement for multiple factors in the activation of migration may explain why migration in vivo occurs only after several days of injury to blood vessels and is dependent on the extent of injury to the underlying media.
